Replies to post #550 on Dendreon Corp fka DNDNQ

[poorgradstudent]

sam,

This was in a seminar about a year ago if memory serves. And yes, it was my first mention of it because I didn't think it was material to DNDN's prospects.

[walldiver]

The very thought that Big Pharma is manipulating DNDN stock is absolutely, laugh-out loud ludicrous...even a BP proxy doing it is ludicrous. I sure hope that the I-Village board hasn't lapsed back into this nonsense like the old Yahoo board. If it has, then I haven't missed anything by not going over there with my limited time.

BP reacts to competitive biologic products from biotechs in other ways...such as running large trials in competing indications, in order to slow down the enrollment for the biologic. BP can afford to pay the lead trial center doctors $10K per patient to enroll them in a BP product's trial. If that doesn't work, then it's by collaboration or buyout.